Original ResearchPatient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
Under a Creative Commons license
open access
Keywords
EORTC QLQ-C30
EORTC QLQ-LC13
Non-small-cell lung cancer
Osimertinib
Patient-reported outcomes
Cited by (0)
© 2019 The Authors. Published by Elsevier Ltd.